Clarity required [Regulatives / Guidelines]

posted by suchit_bhavsar – India, 2021-08-27 07:02 (1340 d 04:27 ago) – Posting: # 22548
Views: 3,349

Dear All,

Hello to every one.

As per latest published draft guideline "Bioequivalence Studies with Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA", under heading Data deletion because of vomiting, one sentence is there like The concentration data for the subject who vomited should be reported

Hence it is required to report concentration data of subject who had vomited for the USFDA studies

Valuable suggestions required

Regards,
Suchit Bhavsar


Edit: Guidance linked. [Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,670 registered users;
76 visitors (0 registered, 76 guests [including 3 identified bots]).
Forum time: 11:29 CEST (Europe/Vienna)

There are two possible outcomes: if the result confirms the
hypothesis, then you’ve made a measurement. If the result is
contrary to the hypothesis, then you’ve made a discovery.    Enrico Fermi

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5